Novel findings regarding treatment obesity and weight-related comorbidities – the systemic literature review
DOI:
https://doi.org/10.12775/QS.2025.37.57002Keywords
obesity, overweight, obesity treatment, tirzepatide, retatrutide, semaglutide, CagriSema, survodutide, orfogliprone, GLP-1 agonist, obesity-related complicationsAbstract
Obesity and overweight are a growing health problem worldwide and are recognized as risk factors for many health complications and increased mortality. Therefore, it is necessary to take decisive action to fight the obesity epidemic to avoid significant costs associated with the treatment of diseases related to excess body weight. Recent years have brought many new drugs that are very effective in obesity treatment and even more are in clinical trials. This review aims to synthesize the literature regarding new drugs and their effectiveness in treating obesity and their impact on related diseases. A systematic search was conducted across multiple sources, including PubMed, Google Scholar, ResearchGate, ClinicalTrials, FDA, and EMA databases. Currently, the most effective medications seem to be tirzepatide and retatrutide, which might provide more than 15% weight loss. However, other drugs show promising results in improving glycemic control, cardiovascular health (semaglutide and tirzepatide), lipid levels, the regression of fibrosis (survodutide), or alleviating OBS symptoms (tirzepatide). Tailored therapy combining both medication’s weight-reducing capacity and the patient’s comorbidities provides the most beneficial effects.
References
WHO Consultation on Obesity (1999: Geneva S, Organization WH. Obesity : preventing and managing the global epidemic : report of a WHO consultation [Internet]. World Health Organization; 2000 [quoted 11 November 2024]. Available on: https://iris.who.int/handle/10665/42330
Koliaki C, Dalamaga M, Liatis S. Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten? Curr Obes Rep. 1 Dicember 2023;12(4):514–27.
Overweight and obesity - BMI statistics [website]. [quoted 9 Dicember 2024]. Available on: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Overweight_and_obesity_-_BMI_statistics
Kosiborod MN, Platz E, Wharton S, le Roux CW, Brueckmann M, Ajaz Hussain S, i in. Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC Heart Fail [website]. 23 November 2024 [quoted 30 November 2024]. Available on: https://www.sciencedirect.com/science/article/pii/S2213177924006620
Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes. 1 luty 2024;1–19.
Althoff MD, Ghincea A, Wood LG, Holguin F, Sharma S. Asthma and Three Colinear Comorbidities: Obesity, OSA, and GERD. J Allergy Clin Immunol Pract. November 2021;9(11):3877–84.
Obesity-diabetes-endocrinopathy – the metabolic connection | Request PDF. ResearchGate [website]. 21 November 2024 [quoted 11 November 2024]. Available on: https://www.researchgate.net/publication/366703695_Obesity-diabetes-endocrinopathy_-_the_metabolic_connection
De Lorenzo A, Gratteri S, Gualtieri P, Cammarano A, Bertucci P, Di Renzo L. Why primary obesity is a disease? J Transl Med. 22 May 2019;17(1):169.
Kloock S, Ziegler CG, Dischinger U. Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery? Pharmacol Ther. 1 November 2023;251:108549.
Duan D, Kim LJ, Jun JC, Polotsky VY. Connecting insufficient sleep and insomnia with metabolic dysfunction. Ann N Y Acad Sci. 13 November 2022;1519(1):94.
Fulton S, Décarie-Spain L, Fioramonti X, Guiard B, Nakajima S. The menace of obesity to depression and anxiety prevalence. Trends Endocrinol Metab. 1 January 2022;33(1):18–35.
Darapaneni H, Lakhanpal S, Chhayani H, Parikh K, Patel M, Gupta V, i in. Sciendo. Rom J Intern Med. 23 March 2024;62(1):3–11.
Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinicalMedicine [website]. 1 April 2023 [quoted 11 November 2024], 58 Available on : https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00059-7/fulltext?utm_source=perplexity
Commissioner O of the. FDA. FDA; 2024 [quoted 9 grudzień 2024]. FDA Approves New Medication for Chronic Weight Management. Available on: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
Kusminski CM, Perez-Tilve D, Müller TD, DiMarchi RD, Tschöp MH, Scherer PE. Transforming obesity: The advancement of multi-receptor drugs. Cell. 25 July 2024;187(15):3829–53.
Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, i in. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 16 November 2024;NEJMoa2410027.
Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, i in. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 25 July 2024;391(4):299–310.
Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, i in. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 3 October 2024;391(13):1193–205.
Kong W, Deng B, Shen X, John C, Haag J, Sinha N, i in. Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer. Gynecol Oncol. 1 December 2024;191:116–23.
Ciardullo S, Muraca E, Vergani M, Invernizzi P, Perseghin G. Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions. Gastroenterol Rep. 26 kwiecień 2024;12:goae029.
(PDF) Pharmacological Treatment of Obesity: A Review of Current and Future Methods. ResearchGate [Internet]. 22 październik 2024 [cytowane 21 listopad 2024]; Dostępne na: https://www.researchgate.net/publication/384263883_Pharmacological_Treatment_of_Obesity_A_Review_of_Current_and_Future_Methods
Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, i in. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. październik 2022;28(10):2083–91.
Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, i in. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. The Lancet. sierpień 2024;404(10454):773–86.
Coutinho W, Halpern B. Pharmacotherapy for obesity: moving towards efficacy improvement. Diabetol Metab Syndr. 3 January 2024;16(1):6.
Kokkorakis M, Chakhtoura M, Rhayem C, Rifai JA, Ghezzawi M, Valenzuela-Vallejo L, i in. Emerging Pharmacotherapies for Obesity: A Systematic Review. Pharmacol Rev [Internet]. 1 January 2024 [quoted 9 November 2024]. Available on: https://pharmrev.aspetjournals.org/content/early/2024/09/20/pharmrev.123.001045
Dehestani B, Stratford NR, Roux CWL. Amylin as a Future Obesity Treatment. J Obes Metab Syndr. 30 December 2021;30(4):320–5.
Eržen S, Tonin G, Eržen DJ, Klen J. Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity. Int J Mol Sci. 26 January 2024;25(3):1517.
Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetology. 2024;67(3):470–82.
le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. March 2024;12(3):162–73.
Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, i in. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 24 July 2024;391(4):311–9.
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, i in. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 7 September 2023;389(10):877–88.
Eli Lilly and Company. A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) [Internet]. clinicaltrials.gov; 2024 October [quoted 9 December 2024]. Report No.: NCT05869903. Available on: https://clinicaltrials.gov/study/NCT05869903
Eli Lilly and Company. A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) [website]. clinicaltrials.gov; 2024 October [quoted 9 December 2024]. Report No.: NCT05872620. Avaliable on: https://clinicaltrials.gov/study/NCT05872620
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Karina Urbańska, Dariusz Popiela, Łukasz Stojak, Filip Kwiatkowski, Katarzyna Grego, Mateusz Grego, Mateusz Baczewski, Witold Czyż
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 144
Number of citations: 0
